Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth
- 8 February 2012
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 159 (3), 384-392
- https://doi.org/10.1016/j.jconrel.2012.01.045
Abstract
No abstract availableKeywords
Funding Information
- NIH/NCI (U01CA151802, U54CA119347, P50 CA128613, P30 CA138292)
This publication has 37 references indexed in Scilit:
- Metabolic genes in cancer: Their roles in tumor progression and clinical implicationsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2010
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticlesProceedings of the National Academy of Sciences, 2009
- Implication of Checkpoint Kinase-dependent Up-regulation of Ribonucleotide Reductase R2 in DNA Damage ResponseJournal of Biological Chemistry, 2009
- The promises and pitfalls of RNA-interference-based therapeuticsNature, 2009
- Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabineBritish Journal of Cancer, 2008
- Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imagingProceedings of the National Academy of Sciences, 2007
- Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNAProceedings of the National Academy of Sciences, 2007
- Physicochemical and Biological Characterization of Targeted, Nucleic Acid-Containing NanoparticlesBioconjugate Chemistry, 2007
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990